Study Description
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is
efficacious and safe for the treatment of aHUS in adult patients who are treatment naive
to complement inhibitor therapy. The study is designed as a multicenter, single-arm, open label study to demonstrate the
efficacy and safety of LNP023 (iptacopan) at a dose of 200 mg b.i.d. in adult patients
with aHUS who are treatment naive to complement inhibitor therapy (including anti-C5
antibody). The study will enroll approximately 50 participants and assess the effects of
iptacopan on a range of efficacy assessments relevant to aHUS including hematological and
kidney parameters, dialysis requirement, changes in chronic kidney disease (CKD) stage,
as well as patient reported outcomes (PRO) for fatigue and quality of life.
Interventions
Iptacopan
Eligibility Criteria
Main Inclusion Criteria:
- Adult patients with evidence of active thrombotic microangiopathy (TMA), including
thrombocytopenia, evidence of hemolysis, and acute kidney injury
- Vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and
Haemophilus influenzae infections are required prior to the start of study
treatment. If the patient has not been previously vaccinated, or if a booster is
required, vaccine should be given according to local regulations, at least 2 weeks
prior to first study drug administration. If study treatment has to start earlier
than 2 weeks post vaccination or before vaccination is given, prophylactic
antibiotic treatment must be administered at the start of study treatment and for at
least 2 weeks after vaccination
Main Exclusion Criteria:
- Treatment with complement inhibitors, including anti-C5 antibody
- ADAMTS13 deficiency (<10% activity or <0.1U/ml), and/or Shiga toxin-related
hemolytic uremic syndrome (STx-HUS), and/or Positive direct Coombs test
- Identified drug exposure-related HUS or HUS related to known genetic defects of
cobalamin C metabolism or known diacylglycerol kinase ε (DGKE) mediated aHUS
- Receiving PE/PI, for 14 days or longer, prior to the start of screening for the
current TMA
- Bone marrow transplantation (BMT)/hematopoietic stem cell transplantation (HSCT),
heart, lung, small bowel, pancreas, or liver transplantation
- Patients with sepsis or active severe systemic bacterial, viral (including COVID-19)
or fungal infection, systemic infection which confounds an accurate diagnosis of
aHUS or impedes the ability to manage the aHUS disease, active infection (or history
of recurrent invasive infections) caused by encapsulated bacteria
- Kidney disease suggestive of other disease than aHUS or of chronic kidney failure or
family history of non-complement mediated genetic kidney disease
- Liver disease or liver injury at screening
- Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or
antiphospholipid antibody positivity or syndrome
- Chronic hemo- or peritoneal dialysis
Other protocol-defined inclusion/exclusion criteria may apply
Study Location
Novartis Investigative Site
Recruiting
Wien,1090,Austria
Novartis Investigative Site
Recruiting
Innsbruck,Tyrol,6020,Austria
Novartis Investigative Site
Recruiting
Brasilia,DF,71635-580,Brazil
Novartis Investigative Site
Recruiting
Salvador,40301-155,Brazil
Novartis Investigative Site
Recruiting
Pernambuco,Recife,50740-900,Brazil
Novartis Investigative Site
Recruiting
Sao Paulo,SP,01327 001,Brazil
Novartis Investigative Site
Recruiting
Porto Alegre,RS,90020-090,Brazil
Novartis Investigative Site
Recruiting
São Paulo,SP,04038-002,Brazil
Novartis Investigative Site
Recruiting
Sao Paulo,SP,05403 000,Brazil
Novartis Investigative Site
Recruiting
Belo Horizonte,MG,30150-221,Brazil
Novartis Investigative Site
Recruiting
Fortaleza,CE,60430 370,Brazil
Novartis Investigative Site
Recruiting
Botucatu,SP,18618-970,Brazil
Novartis Investigative Site
Recruiting
Rio de Janeiro,22270-60,Brazil
Novartis Investigative Site
Recruiting
Shanghai,200025,China
Novartis Investigative Site
Recruiting
Beijing,100034,China
Novartis Investigative Site
Recruiting
Shanxi,710063,China
Novartis Investigative Site
Recruiting
Beijing,100191,China
Novartis Investigative Site
Recruiting
Yantai,Shandong,264000,China
Novartis Investigative Site
Recruiting
Beijing,100730,China
Novartis Investigative Site
Recruiting
Nanjing,Jiangsu,210009,China
Novartis Investigative Site
Recruiting
Guangzhou,Guangdong,510086,China
Novartis Investigative Site
Recruiting
Praha 4,140 00,Czechia
Novartis Investigative Site
Recruiting
Praha,12808,Czechia
Novartis Investigative Site
Recruiting
Ostrava,Poruba,708 52,Czechia
Novartis Investigative Site
Recruiting
Athens,115 27,Greece
Novartis Investigative Site
Recruiting
Heraklion Crete,711 10,Greece
Novartis Investigative Site
Recruiting
Thessaloniki,GR,570 10,Greece
Novartis Investigative Site
Recruiting
Vellore,Tamil Nadu,632517,India
Novartis Investigative Site
Recruiting
Lucknow,Uttar Pradesh,226014,India
Novartis Investigative Site
Recruiting
Hyderabad,Andhra Pradesh,500012,India
Novartis Investigative Site
Recruiting
Chandigarh,Punjab,160012,India
Novartis Investigative Site
Recruiting
Nagpur,Maharashtra,440015,India
Novartis Investigative Site
Recruiting
Chennai,Tamil Nadu,600 006,India
Novartis Investigative Site
Recruiting
Pune,Maharashtra,411011,India
Novartis Investigative Site
Recruiting
Thiruvananthapuram,Kerala,695011,India
Novartis Investigative Site
Recruiting
Bunkyo ku,Tokyo,113 8655,Japan
Novartis Investigative Site
Recruiting
Iruma-gun,Saitama,350-0495,Japan
Novartis Investigative Site
Recruiting
Izumo-city,Shimane,693 8501,Japan
Novartis Investigative Site
Recruiting
Seoul,06591,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03080,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03722,Korea, Republic of
Novartis Investigative Site
Recruiting
Bratislava,833 05,Slovakia
Novartis Investigative Site
Recruiting
Martin,036 59,Slovakia
Novartis Investigative Site
Recruiting
Ljubljana,1000,Slovenia
Novartis Investigative Site
Recruiting
Taichung,40447,Taiwan
Novartis Investigative Site
Recruiting
Taoyuan,33305,Taiwan
Novartis Investigative Site
Recruiting
London,Nw1 2bu,United Kingdom
Novartis Investigative Site
Recruiting
Newcastle Upon Tyne,Ne7 7dn,United Kingdom
Baylor Scott and White Research .
Recruiting
Temple,Texas,76502,United States
Cleveland Clinic Foundation Nephrology and Hypertension
Recruiting
Cleveland,Ohio,44195,United States
Duke University Medical Center .
Recruiting
Durham,North Carolina,27710,United States
University of New Mexico Clin and Transl Science Ctr
Recruiting
Albuquerque,New Mexico,87131-0001,United States
Georgetown University Lombardi Cancer Center
Recruiting
Washington,District of Columbia,20007 2197,United States
USC Norris Cancer Center
Recruiting
Los Angeles,California,90033,United States
Harbor-UCLA Medical Center .
Recruiting
Torrance,California,90502,United States
Montefiore Medical Center .
Recruiting
Bronx,New York,10461,United States
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.